Clinical trial · Observational
Protocole Advanced RadioTherapy ORL
Health Economic Evaluation of Tomotherapy and Dynamic Arctherapy in ENT Epidermoid Carcinoma
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to do health economic evaluation of tomotherapy and dynamic arctherapy (2 techniques exist: RapidArc and Vmat). This study evaluate also local disease control after 18 months in patients with an ENT epidermoid carcinoma and treated by tomotherapy orarctherapy . The number of patients required in this study is: 300: * Number of patients treated with tomotherapy: 120 * Number of patients treated with dynamic arctherapy RapidArc: 120 * Number of patients treated with dynamic arctherapy Vmat: 60 This is a prospective; multicentric and non randomized study.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Head and Neck Squamous Cell Carcinoma | Head and Neck Squamous Cell Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Radiotherapy | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Tomotherapy
- interventionNames
- Radiation: Radiotherapy
- label
- Arc'therapy Vmat
- interventionNames
- Radiation: Radiotherapy
- label
- Arctherapy Rapid'Arc
- interventionNames
- Radiation: Radiotherapy
Primary outcomes (1)
- measure
- The various of cost between tomotherapy and Intensity Modulation Radiation Therapy (IMRT)
- timeFrame
- 18 months
- description
- The purpose of this study is to realise a Health economic evaluation of the various cost between tomotherapy and Intensity Modulation Radiation Therapy (IMRT)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * PS \<= 2 * Age \>= 18 years * Histologically proven carcinoma * Cavum Epidermoïd or undifferentiated carcinoma; or oropharynx epidermoïd carcinoma; or oral cavity epidermoïd carcinoma * Stade T1 to T4 * M0 * Patient with no surgery ( except laser partial surgery and ganglionic cleaning out) * Bilateral ganlionic cervical area irradiation * Covered by a medical insurance. Exclusion Criteria: * Prior history of other malignancies in the last 5 years(except non evolutive ENT cancer or squamous cell carcinoma ) * Re-irradiation indication * Unilateral cervical area irradiation * Post-operative radiotherapy * Patient treated by amifostine * Impossible follow-up
References
Publications (2)
- DERIVEDBibault JE, Dussart S, Pommier P, Morelle M, Huguet M, Boisselier P, Coche-Dequeant B, Alfonsi M, Bardet E, Rives M, Calugaru V, Chajon E, Noel G, Mecellem H, Servagi Vernat S, Perrier L, Giraud P. Clinical Outcomes of Several IMRT Techniques for Patients With Head and Neck Cancer: A Propensity Score-Weighted Analysis. Int J Radiat Oncol Biol Phys. 2017 Nov 15;99(4):929-937. doi: 10.1016/j.ijrobp.2017.06.2456. Epub 2017 Jun 27. PMID 28864403
- DERIVEDBibault JE, Morelle M, Perrier L, Pommier P, Boisselier P, Coche-Dequeant B, Gallocher O, Alfonsi M, Bardet E, Rives M, Calugaru V, Chajon E, Noel G, Mecellem H, Perol D, Dussart S, Giraud P. Toxicity and efficacy of cetuximab associated with several modalities of IMRT for locally advanced head and neck cancer. Cancer Radiother. 2016 Jul;20(5):357-61. doi: 10.1016/j.canrad.2016.05.009. Epub 2016 Jun 23. PMID 27345843